Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares

Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase